Cantor Fitzgerald Reiterates Overweight Rating on Prenetics with Price Target of $31 Following Strong IM8 Growth

Core Insights - Cantor Fitzgerald has reiterated its Overweight rating on Prenetics Global Limited, adjusting the 12-month price target to $31 from $32, reflecting updates related to the planned divestment of its Europa business while maintaining a positive long-term outlook on the company [1][2] Financial Performance - Prenetics reported a 3Q25 revenue of $23.6 million, representing approximately 568% year-over-year growth, with IM8 revenue reaching $17.2 million, up about 76% sequentially and achieving gross margins of around 60% [5] - The company has a customer payback period of approximately 3.9 months and an 80%+ subscription rate, indicating strong unit economics [5] - As of November 10, 2025, Prenetics holds approximately 387 BTC valued at around $41 million, contributing to total liquidity of approximately $120 million [5] Market Position and Valuation - Cantor views Prenetics as undervalued, with PRE trading at just 0.7× EV/2026E revenue compared to approximately 1.1× for consumer-health peers [2] - Cantor forecasts FY2026 revenue of approximately $217 million, driven by continued momentum from IM8 and international expansion [5] Management Commentary - CEO Danny Yeung emphasized that Cantor's ongoing research coverage highlights Prenetics' emergence as a global leader in health and longevity, reinforcing investor understanding of the significant opportunities ahead as IM8 scales internationally [2]